Hjem › T-celle-lymfom › Michigan
T-celle-lymfom kliniske forsøg i Michigan
5 studier for T-celle-lymfom søger deltagere på steder i Michigan.
Byer i Michigan
Officiel studietekst (engelsk)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Roger Cancer Center University of Michigan Health, Ann Arbor
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Wayne State University/Karmanos Cancer Institute, Detroit
- Weisberg Cancer Treatment Center, Farmington Hills
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06724237Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Michigan, Ann Arbor
- Barbara Ann Karmanos Cancer Institute Wayne State University, Detroit
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2025 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- C.S. Mott Children's Hospital, Ann Arbor
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.